November 27, 2024
Loading...
You are here:  Home  >  Latest news  >  Current Article

Amgen’s shares down after obesity drug fails to meet expectations

IN THIS ARTICLE

MarTide, the new weight loss drug from Amgen, works. Not just well enough for Wall Street.

Shares of the Thousand Oaks-based biotech giant fell 10% on Nov. 26 after it announced that MarTide’s latest trial produced a body weight reduction of up to 20%. The results disappointed Wall Street, which had expected results of up to 25%. 

The sell-off in Amgen shares weighed on one major market indicator, contributing heavily to a 200-point drop in the Dow Jones Industrial Average which includes Amgen and 29 other large company stocks. Bloomberg reported the share drop was the largest in 23 years on a percentage basis. 

Analysts believe meeting the 25% weight loss bar will be necessary for Amgen to compete with a new generation of therapies from market leaders Novo Nordisk and Lily. Novo Nordisk’s Wegovy and Lily’s Ozempic have become the latest blockbuster drugs with success in treating stage 2 diabetes and other chronic diseases.

The Amgen trial lasted a year and was widely anticipated. Lily and Novo Nordisk are targeting 25% body mass reduction from their next generation of drugs.